Results 301 to 310 of about 235,967 (343)

Severe cardiopulmonary complications of ketamine: Acute pulmonary Edema in a cardiac patient. [PDF]

Oxf Med Case Reports
Shahzad T, Bhutta ZA, Rehman MAU.
europepmc   +1 more source

Ketofol (Ketamine-Propofol) in Pediatric Awake Neurosurgery: An Anesthetic Perspective. [PDF]

J Med Cases
Abdyli A, Huti G, Grada M, Leka V, Dodaj S, Dashi F, Coniglione F, Lilaj K, Cani A, Drishti A, Bajraktari M, Naco M, Soxhuku A, Domi R.   +13 more
europepmc   +1 more source

Structural Domination and Contradictory Socialization1

Constellations, EarlyView.
Antoine Louette
wiley   +1 more source

Regional blood flow signatures of opioidergic modulation of ketamine in major depressive disorder: a randomised crossover study

Jelen LA, O’Daly O, Zelaya FO, Stone JM, Young AH, Mehta MA.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

New England Journal of Medicine, 2023
BACKGROUND Electroconvulsive therapy (ECT) and subanesthetic intravenous ketamine are both currently used for treatment-resistant major depression, but the comparative effectiveness of the two treatments remains uncertain.
A. Anand, S. Mathew, G. Sanacora, J. Murrough, F. Goes, Murat Altinay, Amy Aloysi, A. Asghar-Ali, B. Barnett, Lee C Chang, K. Collins, S. Costi, Sidra Iqbal, M. Jha, K. Krishnan, D. Malone, Sina Nikayin, S. Nissen, R. Ostroff, I. Reti, S. Wilkinson, K. Wolski, Bo Hu   +22 more
semanticscholar   +1 more source

Long-term safety of ketamine and esketamine in treatment of depression

Expert Opinion on Drug Safety, 2022
Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine (Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment-resistant depression in 2019.
Sina Nikayin, Eva L. Murphy, J. Krystal, S. Wilkinson   +3 more
semanticscholar   +1 more source

A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.

American Journal of Psychiatry, 2021
OBJECTIVE Posttraumatic stress disorder (PTSD) is a chronic and disabling disorder, for which available pharmacotherapies have limited efficacy. The authors' previous proof-of-concept randomized controlled trial of single-dose intravenous ketamine ...
A. Feder, S. Costi, S. Rutter, A. Collins, Usha Govindarajulu, M. Jha, S. Horn, Marin M. Kautz, M. Corniquel, K. Collins, L. Bevilacqua, Andrew Glasgow, Jess Brallier, R. Pietrzak, J. Murrough, D. Charney   +15 more
semanticscholar   +1 more source

Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial.

American Journal of Psychiatry, 2021
OBJECTIVE Adolescent depression is prevalent and is associated with significant morbidity and mortality. Although intravenous ketamine has shown efficacy in adult treatment-resistant depression, its efficacy in pediatric populations is unknown.
J. Dwyer, A. Landeros-Weisenberger, Jessica A. Johnson, Amalia Londoño Tobón, José M. Flores, Madeeha Nasir, Kevin G. Couloures, G. Sanacora, M. Bloch   +8 more
semanticscholar   +1 more source

Importance of ketamine

Veterinary Record, 2016
FURTHER to our recent letter in Veterinary Record (March 12, 2016, vol 178, p 271), we would like to give an update on the international scheduling of ketamine following the 59th meeting of the UN Commission on Narcotic Drugs which took place in Vienna from March 14 to 22. Ketamine was discussed at some length during …
Walt Ingwersen, Polly M Taylor
openaire   +4 more sources